-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In a recent study published inStroke, an authoritative journal in the field of cardiovascular disease, researchers aim to identify the incidence and predictive indicators of acute kidney injury (AKI) and adverse kidney events (AEs) in patients with cerebral hemorrhage, as well as the effects of AKI and kidney AE on patient death or disability.
researchers analyzed data from a multi-center trial that randomly assigned 1,000 patients with initial systolic blood pressure of 180 mmHg to standard buck (systolic pressure target value 140-179 mmHg) and intensive buck (systolic pressure target value 140-179 mmHg) within 4.5 hours of symptom attacks.
the AKI condition by a series of measurements of daily serum creatinine levels after 3 days of random grouping.
AKI and kidney AE were observed in 149 patients (14.9%) and 65 patients (6.5%) respectively in 1,000 patients.
in the multivariate analysis, higher baseline serum creatinine levels (-110μmol/L) were associated with AKI (ratio of 2.4 (95% CI is 1.2-4.5)) and kidney AEs (ratio of 3.1 (95% CI is 1.2-8.1).
the area under the curve of the intravenous nica floor dose is associated with AKI (ratio of 1.003 (95% CI is 1.001-1.005)) and kidney AEs (ratio of 1.003 (95% CI is 1.001-1.006).
AKI patients had a higher risk of death at 90 days (the relative risk was 2.6 (95% CI was 1.6-4.2)) and death or disability (the relative risk was 1.5 (95% CI was 1.3-1.8)), compared to those with kidney AEs.
result, higher baseline blood creatinine levels and higher risk of AKI and renal AE occurred in patients with cerebral hemorrhage who received higher doses of nicadypine.
AKI was associated with a higher mortality or disability rate at 3 months.
.